Clinical Trials Logo

Neuritis clinical trials

View clinical trials related to Neuritis.

Filter by:

NCT ID: NCT03570385 Completed - Optic Neuritis Clinical Trials

Can Diffusion Tensor Imaging (DTI) of the Optic Ways Contributes to Predict the 6 Months Prognosis of Optic Neuritis (ON)?

DTI et NOI
Start date: December 4, 2017
Phase: N/A
Study type: Interventional

Can diffusion tensor imaging (DTI) of the optic ways contributes to predict the 6 months prognosis of Optic Neuritis (ON)?

NCT ID: NCT03543384 Recruiting - Facial Neuritis Clinical Trials

Imaging of Facial Neuritis

Start date: February 20, 2018
Phase:
Study type: Observational

Improved means of positive diagnosis of facial neuritis, the leading cause of peripheral facial palsy

NCT ID: NCT03536559 Terminated - Clinical trials for Relapsing Remitting Multiple Sclerosis

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis

VISIONARY-MS
Start date: November 23, 2018
Phase: Phase 2
Study type: Interventional

The objective of this trial is to assess the efficacy and safety of CNM-Au8 as a remyelinating treatment for vision-impairing MS lesions in participants who have chronic vision impairment as a result of Relapsing-Remitting Multiple Sclerosis. The primary endpoint is to assess the efficacy and safety of CNM-Au8 as a remyelinating therapy in patients with stable RMS. The secondary endpoint is Change in Functional Composite Responder Analysis Score from Baseline to Week 24.

NCT ID: NCT03533426 Completed - Thoracic Neuritis Clinical Trials

Ultrasound-guided Serratus Block and the Emergence of Post-thoracotomy Pain Syndrome

Start date: March 27, 2018
Phase: N/A
Study type: Interventional

The aim of this prospective, single blinded, comparative pilot study is to evaluate U/S guided serratus anterior plane catheter block (SAPB) versus patient-controlled analgesia (PCA) on the emergence of post - thoracotomy pain syndrome (PTPS). The investigator's assumed hypothesis is that; SAPB is an effective thoracic analgesic technique that may reduce the development of PTPS.

NCT ID: NCT03505671 Completed - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer

Start date: August 3, 2018
Phase: N/A
Study type: Interventional

The goal of this study is to obtain preliminary evidence of the effect of 8 acupuncture treatments over 10 weeks in breast and GI cancer patients who are currently receiving or recently completed active neurotoxic chemotherapy and have clinically documented grade 1 or 2 neuropathy.

NCT ID: NCT03493321 Not yet recruiting - Neuritis Clinical Trials

Role of PRF With MTA and Theracal After Pulpotomy in Relieving Pain

Start date: August 22, 2019
Phase: N/A
Study type: Interventional

this research will evaluate the effect of PRF with different bioactive materials in dentistry

NCT ID: NCT03452410 Completed - Vestibular Neuritis Clinical Trials

MRIPositive Diagnosis of Vestibular Neuritis Using Fluid Attenuated Inversion Recuperation (FLAIR) Sequence on a 1.5 Tesla

Start date: February 23, 2018
Phase:
Study type: Observational

Our objective is to allow positive MRI diagnosis of vestibular neuritis by highlighting contrast enhancement of the vestibular nerve on the pathological side of the FLAIR sequence acquired 1h after intravenous gadolinium injection in patients with typical vestibular neuritis. At present, the diagnosis is based on a combination clinical examination / video-head impulse test, and no imaging examination allows the diagnosis to be positive.

NCT ID: NCT03451955 Completed - Multiple Sclerosis Clinical Trials

The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With CIS

Start date: January 19, 2018
Phase: N/A
Study type: Interventional

Disruption of the blood brain barrier (BBB) is associated with inflammatory conditions of the central nervous system (CNS). This clinical trial aims to investigate whether following a gluten-free diet (GFD) for six months can contribute to normalizing BBB permeability in patients with newly diagnosed clinically isolated syndrome (CIS) and multiple sclerosis (MS). Furthermore, the study seeks to identify possible effects of a GFD on markers of systemic as well as CNS inflammation. Lastly, gut permeability is measured in order to examine whether there are any correlations between the permeability of the gut and the BBB as well as the inflammatory state in the intestine and CNS. From a patient's view, potential positive effects of a GFD will be manifested through an alleviation of symptoms, improved quality of life and reduced risk of CIS progressing to MS. Evaluating a possible role of gluten in MS pathogenesis can contribute to directing future research and optimizing treatment protocols.

NCT ID: NCT03441347 Completed - Clinical trials for Neuralgic Amyotrophy

Neuralgic Amyotrophy: Central Reorganization and Rehabilitation After Peripheral Dysfunction

NA-CONTROL
Start date: April 4, 2018
Phase: N/A
Study type: Interventional

This study evaluates the effect of a specific, multidisciplinary and personalized rehabilitation program compared to usual care, on motor control and functional disability in patients with neuralgic amyotrophy. Half of the participants will start with the 17-week specific rehabilitation program while the other half will first continue their usual care for 17 weeks, after which they will also receive the 17-week specific rehabilitation program.

NCT ID: NCT03401879 Recruiting - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis

Start date: February 1, 2018
Phase: N/A
Study type: Interventional

Multiple sclerosis (MS) affects approximately 2.3 million patients worldwide, with a global median prevalence of 33 per 100,000. MS is diagnosed at an average of 30 years and affects twice as many women as men. MS is traditionally diagnosed by the presentation of lesions of the central nervous system, disseminated in time and in space, proven by clinical examination and magnetic resonance imaging. Several anatomical parameters in the eye, both vascular and neural, have been found to be altered in MS patients. Because of its unique optical properties, the eye offers the possibility of the non-invasive assessment of both structural and functional alterations in neuronal tissue. As the neuro-retina is part of the brain, it does not come as a surprise that neuro-degenerative changes in the brain are accompanied by structural and possibly also functional changes in the neuro-retina and the ocular vasculature. The current study seeks to test the hypothesis that beside the known anatomical changes, also functional changes can be detected in the retina of patients with MS. For this purpose, flicker light induced hyperemia will be measured in the retina as a functional test to assess the coupling between neural activity and blood flow. Further, structural parameters such as retinal nerve fiber layer thickness and function parameters such as ocular blood flow and retinal oxygenation will be assessed and compared to age and sex matched controls.